TY - JOUR
T1 - Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer
T2 - Findings from CALGB 89803 (Alliance)
AU - Lee, Seohyuk
AU - Ma, Chao
AU - Zhang, Sui
AU - Ou, Fang Shu
AU - Bainter, Tiffany M.
AU - Niedzwiecki, Donna
AU - Saltz, Leonard B.
AU - Mayer, Robert J.
AU - Whittom, Renaud
AU - Hantel, Alexander
AU - Benson, Al
AU - Atienza, Daniel
AU - Kindler, Hedy
AU - Gross, Cary P.
AU - Irwin, Melinda L.
AU - Meyerhardt, Jeffrey A.
AU - Fuchs, Charles S.
N1 - Funding Information:
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882 and U24CA196171 (to the Alliance for Clinical Trials in Oncology),UG1CA233180,UG1CA233327,UG1CA189858, UG1CA233290, U10CA180867, U10CA138561, U10CA180791, UG1CA233337, R01CA149222, and P30CA016359; U10CA180888 (SWOG); U10CA180820 and UG1CA233320 (ECOG-ACRIN). https://acknowledgments.alliancefound.org. J.A.M. research is supported by the Douglas Gray Woodruff Chair fund, the Guo Shu Shi Fund, Anonymous Family Fund for Innovations in Colorectal Cancer, Project P fund, and the George Stone Family Foundation. Also supported in part by funds from Pharmacia & Upjohn Company (now Pfizer Oncology; to C.S. Fuchs), the Stand-Up-to-Cancer Colorectal Cancer Dream Team (C.S. Fuchs, Grant Number: SU2C-AACR-DT22-17), NIH R01 CA169141, NIH R01 CA118553, and NIH P50 CA127003 to C.S. Fuchs. Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press.
PY - 2022/6
Y1 - 2022/6
N2 - Background: Limited and conflicting findings have been reported regarding the association between social support and colorectal cancer (CRC) outcomes. We sought to assess the influences of marital status and living arrangement on survival outcomes among patients with stage III colon cancer. Patients and Methods: We conducted a secondary analysis of 1082 patients with stage III colon cancer prospectively followed in the CALGB 89803 randomized adjuvant chemotherapy trial. Marital status and living arrangement were both self-reported at the time of enrollment as, respectively, married, divorced, separated, widowed, or never-married, and living alone, with a spouse or partner, with other family, in a nursing home, or other. Results: Over a median follow-up of 7.6 years, divorced/separated/widowed patients experienced worse outcomes relative to those married regarding disease free-survival (DFS) (hazards ratio (HR), 1.44 (95% CI, 1.14-1.81); P =.002), recurrence-free survival (RFS) (HR, 1.35 (95% CI, 1.05-1.73); P = .02), and overall survival (OS) (HR, 1.40 (95% CI, 1.08-1.82); P =.01); outcomes were not significantly different for never-married patients. Compared to patients living with a spouse/partner, those living with other family experienced a DFS of 1.47 (95% CI, 1.02-2.11; P = .04), RFS of 1.34 (95% CI, 0.91-1.98; P = .14), and OS of 1.50 (95% CI, 1.00-2.25; P =.05); patients living alone did not experience significantly different outcomes. Conclusion: Among patients with stage III colon cancer who received uniform treatment and follow-up within a nationwide randomized clinical trial, being divorced/separated/widowed and living with other family were significantly associated with greater colon cancer mortality. Interventions enhancing social support services may be clinically relevant for this patient population. Trial Registration: ClinicalTrials.gov
AB - Background: Limited and conflicting findings have been reported regarding the association between social support and colorectal cancer (CRC) outcomes. We sought to assess the influences of marital status and living arrangement on survival outcomes among patients with stage III colon cancer. Patients and Methods: We conducted a secondary analysis of 1082 patients with stage III colon cancer prospectively followed in the CALGB 89803 randomized adjuvant chemotherapy trial. Marital status and living arrangement were both self-reported at the time of enrollment as, respectively, married, divorced, separated, widowed, or never-married, and living alone, with a spouse or partner, with other family, in a nursing home, or other. Results: Over a median follow-up of 7.6 years, divorced/separated/widowed patients experienced worse outcomes relative to those married regarding disease free-survival (DFS) (hazards ratio (HR), 1.44 (95% CI, 1.14-1.81); P =.002), recurrence-free survival (RFS) (HR, 1.35 (95% CI, 1.05-1.73); P = .02), and overall survival (OS) (HR, 1.40 (95% CI, 1.08-1.82); P =.01); outcomes were not significantly different for never-married patients. Compared to patients living with a spouse/partner, those living with other family experienced a DFS of 1.47 (95% CI, 1.02-2.11; P = .04), RFS of 1.34 (95% CI, 0.91-1.98; P = .14), and OS of 1.50 (95% CI, 1.00-2.25; P =.05); patients living alone did not experience significantly different outcomes. Conclusion: Among patients with stage III colon cancer who received uniform treatment and follow-up within a nationwide randomized clinical trial, being divorced/separated/widowed and living with other family were significantly associated with greater colon cancer mortality. Interventions enhancing social support services may be clinically relevant for this patient population. Trial Registration: ClinicalTrials.gov
KW - clinical trial
KW - colonic neoplasms
KW - marital status
KW - residence characteristics
KW - survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85131772179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131772179&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyab070
DO - 10.1093/oncolo/oyab070
M3 - Article
C2 - 35641198
AN - SCOPUS:85131772179
SN - 1083-7159
VL - 27
SP - E494-E505
JO - Oncologist
JF - Oncologist
IS - 6
ER -